MXPA04002404A - Ligandos novedosos para los sitios hisb10zn2+ del hexamero de insulina en estado r. - Google Patents
Ligandos novedosos para los sitios hisb10zn2+ del hexamero de insulina en estado r.Info
- Publication number
- MXPA04002404A MXPA04002404A MXPA04002404A MXPA04002404A MXPA04002404A MX PA04002404 A MXPA04002404 A MX PA04002404A MX PA04002404 A MXPA04002404 A MX PA04002404A MX PA04002404 A MXPA04002404 A MX PA04002404A MX PA04002404 A MXPA04002404 A MX PA04002404A
- Authority
- MX
- Mexico
- Prior art keywords
- hisb10
- novel ligands
- ligands
- novel
- insulin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Se describen ligandos novedosos para los sitios HisB10 Zn+2 del hexamero de insulina en el estado R que pueden prolongar la accion de las preparaciones de insulina.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200101337 | 2001-09-14 | ||
US32392501P | 2001-09-21 | 2001-09-21 | |
DKPA200201066 | 2002-07-05 | ||
US39605102P | 2002-07-10 | 2002-07-10 | |
PCT/DK2002/000595 WO2003027081A2 (en) | 2001-09-14 | 2002-09-13 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04002404A true MXPA04002404A (es) | 2004-05-31 |
Family
ID=27439845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04002404A MXPA04002404A (es) | 2001-09-14 | 2002-09-13 | Ligandos novedosos para los sitios hisb10zn2+ del hexamero de insulina en estado r. |
Country Status (15)
Country | Link |
---|---|
US (1) | US7879893B2 (es) |
EP (1) | EP1429763B1 (es) |
JP (1) | JP4554207B2 (es) |
CN (1) | CN1558762A (es) |
AT (1) | ATE363278T1 (es) |
BR (1) | BR0212522A (es) |
CA (1) | CA2460541A1 (es) |
CZ (1) | CZ2004313A3 (es) |
DE (1) | DE60220424T2 (es) |
ES (1) | ES2288195T3 (es) |
HU (1) | HUP0401492A3 (es) |
MX (1) | MXPA04002404A (es) |
NO (1) | NO20041494L (es) |
PL (1) | PL369119A1 (es) |
WO (1) | WO2003027081A2 (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070060606A1 (en) * | 1999-10-07 | 2007-03-15 | Robertson Harold A | Compounds and methods for modulating phosphodiesterase 10A |
US7078423B2 (en) * | 2002-07-18 | 2006-07-18 | Inotek Pharmaceuticals Corporation | 5-Aryltetrazole compounds, compositions thereof, and uses therefor |
US7087631B2 (en) * | 2002-07-18 | 2006-08-08 | Inotek Pharmaceuticals Corporation | Aryltetrazole compounds, and compositions thereof |
US20040063098A1 (en) * | 2002-09-26 | 2004-04-01 | Hargreaves John S. | Methods for producing multilayer ligand arrays |
WO2004043955A1 (en) * | 2002-11-13 | 2004-05-27 | Rigel Pharmaceuticals, Inc. | Rhodanine derivatives and pharmaceutical compositions containing them |
ATE378063T1 (de) * | 2002-12-20 | 2007-11-15 | Novo Nordisk As | Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-liganden |
US20050065066A1 (en) * | 2002-12-20 | 2005-03-24 | Kaarsholm Niels Christian | Stabilised insulin compositions |
US7521465B2 (en) * | 2003-01-17 | 2009-04-21 | Bexel Pharmaceuticals, Inc. | Diphenyl ether derivatives |
US7781464B2 (en) | 2003-01-17 | 2010-08-24 | Bexel Pharmaceuticals, Inc. | Heterocyclic diphenyl ethers |
BRPI0408229A (pt) * | 2003-03-11 | 2006-02-21 | Novo Nordisk As | preparação farmacêutica, métodos para preparar um ligando de ligação de zinco, para prolongar a ação de uma preparação de insulina estabilizada por ácido e para tratar diabete do tipo 1 ou tipo 2, e, uso de uma preparação |
US20060258561A1 (en) * | 2003-03-13 | 2006-11-16 | Novo Nordisk A/S | Novel NPH insulin preparations |
CA2531170C (en) * | 2003-07-02 | 2011-05-10 | Teva Gyogyszergyar Reszvenytarsasag | Aztreonam l-lysine and methods for the preparation thereof |
US7087576B2 (en) * | 2003-10-07 | 2006-08-08 | Bexel Pharmaceuticals, Inc. | Dipeptide phenyl ethers |
US7037927B2 (en) * | 2003-10-16 | 2006-05-02 | Abbott Laboratories | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor |
WO2005054291A1 (en) | 2003-12-03 | 2005-06-16 | Novo Nordisk A/S | Single-chain insulin |
EP1757591A4 (en) | 2004-05-26 | 2010-05-05 | Eisai R&D Man Co Ltd | ZIMTSÄUREAMIDVERBINDUNG |
KR20070029247A (ko) | 2004-07-08 | 2007-03-13 | 노보 노르디스크 에이/에스 | 폴리펩티드 연장 태그 |
EP1768694A1 (en) * | 2004-07-09 | 2007-04-04 | Novo Nordisk A/S | Phamaceutical preparations comprising insulin |
BRPI0514133A (pt) * | 2004-08-05 | 2008-05-27 | Hoffmann La Roche | compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i |
WO2006029634A2 (en) * | 2004-09-17 | 2006-03-23 | Novo Nordisk A/S | Pharmaceutical compositions containing insulin and insulinotropic peptide |
RU2430920C2 (ru) * | 2004-09-28 | 2011-10-10 | Оцука Фармасьютикал Ко., Лтд. | Карбостирильное соединение |
KR20070083781A (ko) | 2004-10-26 | 2007-08-24 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 화합물의 비정질체 |
TWI370130B (en) | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
TWI378091B (en) | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
TW200800978A (en) * | 2006-03-23 | 2008-01-01 | Otsuka Pharma Co Ltd | Carbazole compound |
JP5191155B2 (ja) * | 2006-03-27 | 2013-04-24 | 大塚製薬株式会社 | カルボスチリル化合物からなる医薬 |
TW200848054A (en) | 2007-02-28 | 2008-12-16 | Eisai R&D Man Co Ltd | Two cyclic oxomorpholine derivatives |
AR068121A1 (es) | 2007-08-31 | 2009-11-04 | Eisai R&D Man Co Ltd | Compuestos multiciclicos para tratar enfermedades neurodegenerativas |
US7935815B2 (en) | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
US9169219B2 (en) | 2012-02-21 | 2015-10-27 | Bayer Intellectual Property Gmbh | Herbicidally active 4-nitro-substituted N-(tetrazol-5-yl)-, N-(triazol-5-yl)-, and N-(1,3,4-0XADIAZOL-2-yl)aryl carboxylic acid amides |
EP2844260A4 (en) * | 2012-04-30 | 2016-06-29 | Anderson Gaweco | ROR MODULATORS AND ITS USES |
KR101942752B1 (ko) * | 2012-11-05 | 2019-01-28 | 주식회사 엘지화학 | Gpr120 효능제로서의 티오아릴 유도체 |
JP6156845B2 (ja) * | 2014-03-04 | 2017-07-05 | 株式会社島津製作所 | マトリックス支援レーザ脱離イオン化質量分析用マトリックス |
CA2968884A1 (en) * | 2014-12-10 | 2016-06-16 | Massachusetts Institute Of Technology | Fused 1,3-azole derivatives useful for the treatment of proliferative diseases |
EP3229807A4 (en) | 2014-12-11 | 2018-10-17 | President and Fellows of Harvard College | Inhibitors of cellular necrosis and related methods |
EP3282846A4 (en) * | 2015-03-23 | 2018-09-26 | University of Miami | Inhibitors of the notch transcriptional activation complex and methods for use of the same |
CA3012846A1 (en) | 2016-02-16 | 2017-08-24 | Massachusetts Institute Of Technology | Max binders as myc modulators and uses thereof |
US11325901B2 (en) * | 2016-06-28 | 2022-05-10 | University Of Kentucky Research Foundation | Prostaglandin E synthase inhibitors and methods for utilizing the same |
EP3558992A4 (en) * | 2016-12-15 | 2020-12-02 | ONO Pharmaceutical Co., Ltd. | ACTIVATOR OF TREK (TWIK-ASSOCIATED K + CHANNELS) CHANNELS |
CN112351975A (zh) * | 2018-03-16 | 2021-02-09 | 俄克拉何马大学董事会 | 过氧化物酶体增殖物活化受体α的激动剂和使用方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DOP1982004086A (es) | 1981-08-27 | 1988-03-22 | Lilly Co Eli | Formula farmaceutica que comprende insulina humana y proinsulina humana |
US5646120A (en) * | 1990-10-24 | 1997-07-08 | Allelix Biopharmaceuticals, Inc. | Peptide-based inhibitors of HIV replication |
US5830999A (en) | 1995-01-26 | 1998-11-03 | Regents Of The University Of California | Stabilization of insulin through ligand binding interations |
DE69914934T2 (de) * | 1998-11-18 | 2005-01-05 | Novo Nordisk A/S | Stabile, wässrige insulin-präparate ohne phenol und cresol |
-
2002
- 2002-09-13 HU HU0401492A patent/HUP0401492A3/hu unknown
- 2002-09-13 JP JP2003530671A patent/JP4554207B2/ja not_active Expired - Fee Related
- 2002-09-13 ES ES02774468T patent/ES2288195T3/es not_active Expired - Lifetime
- 2002-09-13 US US10/332,541 patent/US7879893B2/en not_active Expired - Fee Related
- 2002-09-13 CA CA002460541A patent/CA2460541A1/en not_active Abandoned
- 2002-09-13 MX MXPA04002404A patent/MXPA04002404A/es not_active Application Discontinuation
- 2002-09-13 CZ CZ2004313A patent/CZ2004313A3/cs unknown
- 2002-09-13 AT AT02774468T patent/ATE363278T1/de not_active IP Right Cessation
- 2002-09-13 EP EP02774468A patent/EP1429763B1/en not_active Expired - Lifetime
- 2002-09-13 CN CNA028203402A patent/CN1558762A/zh active Pending
- 2002-09-13 WO PCT/DK2002/000595 patent/WO2003027081A2/en active IP Right Grant
- 2002-09-13 PL PL02369119A patent/PL369119A1/xx not_active Application Discontinuation
- 2002-09-13 DE DE60220424T patent/DE60220424T2/de not_active Expired - Lifetime
- 2002-09-13 BR BR0212522-6A patent/BR0212522A/pt not_active IP Right Cessation
-
2004
- 2004-04-13 NO NO20041494A patent/NO20041494L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ES2288195T3 (es) | 2008-01-01 |
US20030229120A1 (en) | 2003-12-11 |
EP1429763A2 (en) | 2004-06-23 |
NO20041494L (no) | 2004-04-13 |
PL369119A1 (en) | 2005-04-18 |
WO2003027081A2 (en) | 2003-04-03 |
ATE363278T1 (de) | 2007-06-15 |
HUP0401492A2 (hu) | 2004-11-29 |
WO2003027081A3 (en) | 2004-03-25 |
CN1558762A (zh) | 2004-12-29 |
DE60220424T2 (de) | 2008-03-06 |
HUP0401492A3 (en) | 2008-05-28 |
CA2460541A1 (en) | 2003-04-03 |
CZ2004313A3 (cs) | 2004-07-14 |
EP1429763B1 (en) | 2007-05-30 |
US7879893B2 (en) | 2011-02-01 |
JP2005508335A (ja) | 2005-03-31 |
DE60220424D1 (de) | 2007-07-12 |
BR0212522A (pt) | 2004-08-10 |
JP4554207B2 (ja) | 2010-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA04002404A (es) | Ligandos novedosos para los sitios hisb10zn2+ del hexamero de insulina en estado r. | |
MXPA05009565A (es) | Preparaciones farmaceuticas que comprenden insulina estabilizada con acido. | |
YU9404A (sh) | Multimerna, usmerena kontrastna sredstva na bazi peptida | |
JO2410B1 (en) | 6. Replaced pyrido-pyrimidines | |
IL147803A0 (en) | 28-epirapalogs | |
SV2003001076A (es) | Compuestos y procedimientos antitumorales ref. x-14776 | |
MXPA04001560A (es) | Premezclas de glp-1 e insulina basal. | |
YU15299A (sh) | Farmaceutski sastavi | |
WO2003103571A3 (en) | VACCINES AGAINST FLAVIVIRUSES | |
BG105028A (en) | Bridged indenopyrrolocarbazoles | |
GB0128277D0 (en) | Pharmaceutical compositions | |
IL152411A0 (en) | Zolpidem hemitartrate | |
JO2242B1 (en) | Phosphatase inhibitors | |
AU2003290592A1 (en) | Antitumor benzoylsulfonamides | |
AU2003291972A8 (en) | Pharmaceutical compositions comprising insulin and legends of insulin hexamer | |
DE69811733T2 (de) | Punktkontaktverdichtung von gesintertem metallpulver | |
WO2003092632A3 (en) | Cyclic peptide anti-cancer agents and methods | |
AP2001002220A0 (en) | Calcilytic compounds. | |
PT1435991E (pt) | Utilização de aplidina para o tratamento de cancro pancreático | |
AP2002002547A0 (en) | Calcilytic compounds. | |
SG185137A1 (en) | Biologically active peptides | |
EP1383511A4 (en) | CALCILYTIC COMPOUNDS | |
TW200510276A (en) | Calcilytic compounds | |
GB0113920D0 (en) | Composition | |
AU148415S (en) | Bottle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |